LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

LLY

977.6

-2.15%↓

JNJ

242.96

-0.06%↓

ABBV

225.37

-0.98%↓

NVS

154.16

-0.82%↓

AZN

191.88

-0.58%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

27.64 -3.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.59

Max

28.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.542 61.417
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+43.53% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	105M 1.7B
Ankstesnė atidarymo kaina	31.13
Ankstesnė uždarymo kaina	27.64

Naujienos nuotaikos

By Acuity

67%

33%

306 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-12 23:12; UTC

Karštos akcijos

Stocks to Watch: Adobe, Mission Produce, Buzzfeed, Ulta

2026-03-12 22:15; UTC

Uždarbis

Wheaton Precious Metals Logs Higher 4Q Net Income, Boosts Dividend 18%

2026-03-12 21:42; UTC

Svarbiausios naujienos

Stryker Says Cyberattack Disruption Is Continuing

2026-03-12 21:29; UTC

Svarbiausios naujienos

Correction to War in Iran May Upend Brazil Central Bank's Plans Article

2026-03-12 21:27; UTC

Uždarbis

Adobe CEO to Depart as AI Boosts Sales -- Update

2026-03-12 20:46; UTC

Uždarbis

Adobe Posts Higher Sales With CEO Set to Depart

2026-03-12 20:21; UTC

Svarbiausios naujienos

Soybean Futures Higher on Instability in Iran --Daily Grain Highlights

2026-03-12 23:57; UTC

Rinkos pokalbiai

Gold Edges Higher Amid Ongoing Middle East Conflict -- Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-03-12 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Tariff Measures, Trade Tensions Weighed on Results >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Middle East Situation Have Added to Future Uncertainity >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas: Charter Market Remains Exceptionally Tight With Vessels in Short Supply >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Rev $9.72B Vs. $10.70B >0316.HK

2026-03-12 22:13; UTC

Uždarbis

Orient Overseas 2025 Net $1.51B Vs. Net $2.58 >0316.HK

2026-03-12 22:13; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-03-12 22:13; UTC

Rinkos pokalbiai

Uždarbis

Adobe Says Customers Want to Try AI Products for Free First -- Market Talk

2026-03-12 21:16; UTC

Įsigijimai, susijungimai, perėmimai

Alexander & Baldwin: JV Formed by Affil of MW Group and Funds Affiliated With Blackstone and DivcoWest Completed Acquisition of All Outstanding A&B Common Shrs >ALEX

2026-03-12 21:04; UTC

Uždarbis

Adobe Earnings Beat Is Overshadowed by CEO Departure. The Stock Is Sliding. -- Barrons.com

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Adj EPS $1.22 >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Sales $865M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q Net $558.3M >WPM

2026-03-12 21:02; UTC

Uždarbis

Wheaton Precious Metals 4Q EPS $1.23 >WPM

2026-03-12 20:57; UTC

Rinkos pokalbiai

Svarbiausios naujienos

No Need For Canada Rate Increases Amid Jump in Bond Yields -- Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Financial Services Roundup: Market Talk

2026-03-12 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-03-12 20:15; UTC

Įsigijimai, susijungimai, perėmimai

Eaton Completes Acquisition Of Leading Liquid-cooling Solutions Provider Boyd Thermal, Creating An Industry-leading Grid-to-chip Solution For Data Centers >ETN

2026-03-12 20:10; UTC

Uždarbis

Adobe Sees 2Q Rev $6.43B-$6.48B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe 1Q Rev $6.4B >ADBE

2026-03-12 20:05; UTC

Uždarbis

Adobe Sees 2Q Adj EPS $5.80-Adj EPS $5.85 >ADBE

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

43.53% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 43.53%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

306 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.